NASDAQ$PGEN
Precigen Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Precigen's financial results for Q1 2024 were reported, highlighting the pivotal Phase 2 study data of PRGN-2012 and the anticipation of a rolling BLA submission in the second half of 2024.
Precigen reported its Q1 2024 financial results, noting a decrease in total revenues and an increase in research and development expenses. The company is preparing for a potential commercial launch of PRGN-2012 in 2025 and is evaluating financing opportunities to strengthen its balance sheet.
- Pivotal Phase 2 study data of PRGN-2012 for recurrent respiratory papillomatosis (RRP) will be presented at the 2024 ASCO Annual Meeting.
- PRGN-2012 rolling BLA submission is anticipated in the second half of 2024, with commercial readiness activities underway for a potential launch in 2025.
- Two trial-in-progress presentations for PRGN-2009 in combination with pembrolizumab for recurrent/metastatic cervical cancer and oropharyngeal cancer to be presented at ASCO.
- Cash, cash equivalents, and short-term investments totaled $44.8 million as of March 31, 2024.
Headline financials
Revenue & EPS history
Precigen · Revenue · Quarterly
$1.07M
Revenue by segment
Precigen · $18.4M total across 3 segments · Q4 2020
- Service revenue$14.3M+18.1%77.7%
- Product revenue$3.95M-25.4%21.5%
- Collab & licensing$148K-44.6%0.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
+0.4%
Avg return
Earnings day
+1.6%
Avg return
5 days after
+1.4%
Avg return
30 days after
50%
26 / 52 earnings
Positive
+31.0%
Q2 2023
Best reaction
-38.9%
Q4 2018
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +1.7% | -0.2% | — | |
| Q3 2025 | +25.6% | +9.3% | -4.4% | |
| Q2 2025 | +6.1% | +63.9% | +110.6% | |
| Q1 2025 | -2.8% | -5.7% | +0.7% | |
| Q4 2024 | +0.6% | -4.5% | -22.3% | |
| Q3 2024 | -10.4% | -13.0% | -26.1% | |
| Q1 2024 | +6.7% | +2.2% | +25.9% | |
| Q4 2023 | +3.6% | +0.7% | -5.0% | |
| Q3 2023 | -13.5% | -19.8% | -6.3% | |
| Q2 2023 | +31.0% | +43.1% | +39.7% | |
| Q1 2023 | -9.5% | -4.0% | -6.3% | |
| Q4 2022 | +16.4% | -6.0% | -15.5% | |
| Q3 2022 | +11.2% | +18.1% | -2.5% | |
| Q2 2022 | +11.6% | +14.5% | +11.1% | |
| Q1 2022 | +3.2% | +8.0% | +23.2% | |
| Q4 2021 | -1.3% | -10.2% | -6.2% | |
| Q3 2021 | -7.1% | -11.8% | -33.3% | |
| Q2 2021 | +8.6% | +10.4% | +10.6% | |
| Q1 2021 | -0.2% | +5.7% | +9.5% | |
| Q4 2020 | +1.7% | +0.1% | -18.4% | |
| Q3 2020 | +22.2% | +20.4% | +69.7% | |
| Q2 2020 | -5.7% | -8.8% | -1.0% | |
| Q1 2020 | -5.9% | -4.2% | -4.7% | |
| Q4 2019 | -14.5% | -19.0% | -27.4% | |
| Q3 2019 | -1.1% | +2.0% | +6.3% | |
| Q2 2019 | -7.2% | -10.3% | -23.4% | |
| Q1 2019 | -1.1% | +0.7% | +22.2% | |
| Q4 2018 | -38.9% | -39.4% | -36.5% | |
| Q3 2018 | -19.3% | -24.4% | -32.1% | |
| Q2 2018 | -5.7% | -4.6% | -2.9% | |
| Q1 2018 | -19.5% | -13.0% | -9.3% | |
| Q4 2017 | +23.6% | +20.9% | +17.7% | |
| Q3 2017 | -25.3% | -19.7% | -15.9% | |
| Q2 2017 | -5.2% | -4.0% | -15.0% | |
| Q1 2017 | +21.5% | +32.0% | +15.0% | |
| Q4 2016 | +5.8% | +2.1% | -11.0% | |
| Q3 2016 | +14.1% | +24.0% | +15.7% | |
| Q2 2016 | +3.3% | +4.5% | +0.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q4 2015 | -0.1% | — | — | |
| Q3 2015 | +9.7% | — | — | |
| Q2 2015 | -17.8% | — | — | |
| Q1 2015 | +3.2% | — | — | |
| Q4 2014 | +17.3% | — | — | |
| Q3 2014 | -3.9% | — | — | |
| Q2 2014 | -2.9% | — | — | |
| Q1 2013 | +2.9% | — | — | |
| Q1 2014 | -11.7% | — | — | |
| Q4 2013 | +5.5% | — | — | |
| Q3 2012 | +3.6% | — | — | |
| Q3 2013 | +3.6% | — | — | |
| Q2 2013 | -7.8% | — | — | |
| Q4 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro